leverages this principle through Proteolysis Targeting Chimera (PROTAC®) technology, which selectively degrades pathological proteins by linking them to E3 ubiquitin ligases. The major advantage of ...
ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s ...
The two companies will also share costs and profits from the drug, which will start a phase 3 programme next year. The buy-in is another endorsement of Arvinas' PROTAC drugs, bifunctional ...
These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC ... that the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback